M. O. Maiwand
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
M. O. Maiwand has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
G. Asimakopoulos
Department of Thoracic Surgery Harefield Hospital Harefield, Middlesex England UB9 6JH
1 shared publicationGeorge Asimakopoulos
Department of Thoracic Surgery, Harefield Hospital, Middlesex, United Kingdom
1 shared publicationJ.E Beeson
Department of Thoracic Surgery, Harefield Hospital, Harefield, Middlesex UB9 6JH, UK
1 shared publicationJ.M Evans
Department of Thoracic Surgery, Harefield Hospital, Harefield, Middlesex UB9 6JH, UK
1 shared publicationJane Chambers
Department of Thoracic Surgery, Harefield Hospital, Middlesex, United Kingdom
1 shared publicationRobert Glynne-Jones
Department of Oncology, Mount Vernon Hospital, Middlesex, United Kingdom
1 shared publication
Latest Publications
- Open Access
- 1 February 2006
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 81 (2) , 718-721
Direct Cryosurgery for Inoperable Metastatic Disease of the Lung
- 1 February 2006
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 81 (2) , 718-721
Open AccessDirect Cryosurgery for Inoperable Metastatic Disease of the Lung
- Open Access
- 1 April 2004
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 3 (2) , 143-150
Cryosurgery for Lung Cancer: Clinical Results and Technical Aspects
Lung carcinoma is the most frequently diagnosed malignancy in the world, with the incidence increasing through the 20th century. Presentation may be as a tumor mass primarily obstructing the central bronchial lumen, or a mass infiltrating lung tissue. Cryosurgery can be used as a method of palliative treatment for both these endobronchial and extra-bronchial presentations. The aim of this study is two-fold: to present data relating to our extensive experience in treating obstructing endobronchial tumors and to present our initial results of direct cryosurgery to infiltrating lung tumor masses. During a nine-year period, 521 consecutive patients (male:female ratio 1.8:1) with a mean age of 67.9 years who had advanced obstructive tracheobronchial malignant tumors underwent cryosurgery with a mean of 2.4 treatments per patient. Hemoptysis, cough, dyspnoea and chest pain improved by at least one class in 76.4%, 69.0%, 59.25% and 42.6% (p<0.01) of symptomatic patients respectively. Quality of life studies showed that the mean Karnofsky score improved from 60 ± 7 to 75 ± 8 and the mean WHO score from 3.04 ± 0.7 to 2.20 ± 0.56. There were 7 (1.2%) in-hospital deaths, and 2-year survival was 15.9%. Direct cryosurgery to carcinoma of the lung was performed on 15 patients at exploratory thoracotomy. Results showed an increase in FEV1 from 1.80 ± 0.6 liters to 1.95 ± 0.8 (8.3%) liters and in FVC from 2.50 ± 0.8 to 2.68 ± 0.8 liters (7.2%). The Karnofsky score improved from 68 ± 9 to 78 ± 10 and the WHO score from 2.63 ± 0.81 to 2.38 ± 0.78 (9.6%). Major symptoms including cough, dyspnoea, and hemoptysis were assessed and showed improvement in 77.8%, 66.7%, and 100% (p<0.01) of symptomatic patients respectively. Patients were followed for a mean period of 18 months (range 4–84 months). Median survival from the date of surgery (Kaplan-Meier, 95%Cl) was 11.6 (6.8 to 18.2) months, range 1 to 84 months. Cryosurgery provides a safe and effective method for the palliation of advanced central bronchial obstructive tumors, and compares favorably with other methods in terms of safety, cost, and complications. Initial experience suggests that similar palliation may be achieved by cryosurgery applied to advanced parenchymal tumor masses.
- 1 April 2004
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 3 (2) , 143-150
Open AccessCryosurgery for Lung Cancer: Clinical Results and Technical Aspects
Lung carcinoma is the most frequently diagnosed malignancy in the world, with the incidence increasing through the 20th century. Presentation may be as a tumor mass primarily obstructing the central bronchial lumen, or a mass infiltrating lung tissue. Cryosurgery can be used as a method of palliative treatment for both these endobronchial and extra-bronchial presentations. The aim of this study is two-fold: to present data relating to our extensive experience in treating obstructing endobronchial tumors and to present our initial results of direct cryosurgery to infiltrating lung tumor masses. During a nine-year period, 521 consecutive patients (male:female ratio 1.8:1) with a mean age of 67.9 years who had advanced obstructive tracheobronchial malignant tumors underwent cryosurgery with a mean of 2.4 treatments per patient. Hemoptysis, cough, dyspnoea and chest pain improved by at least one class in 76.4%, 69.0%, 59.25% and 42.6% (p<0.01) of symptomatic patients respectively. Quality of life studies showed that the mean Karnofsky score improved from 60 ± 7 to 75 ± 8 and the mean WHO score from 3.04 ± 0.7 to 2.20 ± 0.56. There were 7 (1.2%) in-hospital deaths, and 2-year survival was 15.9%. Direct cryosurgery to carcinoma of the lung was performed on 15 patients at exploratory thoracotomy. Results showed an increase in FEV1 from 1.80 ± 0.6 liters to 1.95 ± 0.8 (8.3%) liters and in FVC from 2.50 ± 0.8 to 2.68 ± 0.8 liters (7.2%). The Karnofsky score improved from 68 ± 9 to 78 ± 10 and the WHO score from 2.63 ± 0.81 to 2.38 ± 0.78 (9.6%). Major symptoms including cough, dyspnoea, and hemoptysis were assessed and showed improvement in 77.8%, 66.7%, and 100% (p<0.01) of symptomatic patients respectively. Patients were followed for a mean period of 18 months (range 4–84 months). Median survival from the date of surgery (Kaplan-Meier, 95%Cl) was 11.6 (6.8 to 18.2) months, range 1 to 84 months. Cryosurgery provides a safe and effective method for the palliation of advanced central bronchial obstructive tumors, and compares favorably with other methods in terms of safety, cost, and complications. Initial experience suggests that similar palliation may be achieved by cryosurgery applied to advanced parenchymal tumor masses.
- 1 February 2004
- Published by Elsevier in Cryobiology
- Vol. 48 (1) , 55-61
The application of cryosurgery in the treatment of lung cancer
- 1 February 2004
- Published by Elsevier in Cryobiology
- Vol. 48 (1) , 55-61
The application of cryosurgery in the treatment of lung cancer
- 1 November 2001
- Vol. 11 (4) , 791-811
Endobronchial cryosurgery.
The use of cryosurgery in the tracheobronchial region has been established for a considerable time, and it has been proved to provide a safe, rapid, and effective method for the restoration of patency in blocked tracheobronchial lumen. It also improves symptoms, respiratory function, and quality of life. The technique is easy to perform, economical, has minimal complications, and is well tolerated by the patient. Cryosurgery often leads to sufficient improvement in the patients' condition such that they can tolerate further treatments, such as radiotherapy or chemotherapy, thus providing a better outcome and improved quality of life and survival.
- 1 November 2001
- Vol. 11 (4) , 791-811
Endobronchial cryosurgery.
The use of cryosurgery in the tracheobronchial region has been established for a considerable time, and it has been proved to provide a safe, rapid, and effective method for the restoration of patency in blocked tracheobronchial lumen. It also improves symptoms, respiratory function, and quality of life. The technique is easy to perform, economical, has minimal complications, and is well tolerated by the patient. Cryosurgery often leads to sufficient improvement in the patients' condition such that they can tolerate further treatments, such as radiotherapy or chemotherapy, thus providing a better outcome and improved quality of life and survival.